Literature DB >> 17570320

Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Rakesh K Singh1, Michelle L Varney, Cheryl Leutzinger, Julie M Vose, Philip J Bierman, Suleyman Buyukberber, Kazuhiko Ino, Kevin Loh, Craig Nichols, David Inwards, Robert Rifkin, James E Talmadge.   

Abstract

In sequential studies, we compared immune reconstitution following high-dose chemotherapy (HDT) and stem cell transplantation (SCT) using intact mobilized peripheral blood stem cell (PSC) in intermediate grade non-Hodgkin's lymphoma (NHL) patients and CD34(+), lineage-negative (Lin(-)), Thy-1(lo) (CD34(+)Lin(-)Thy-1(lo)) stem cells in low-grade NHL patients. Cytokine expression and cellular phenotype and function were used as the basis of comparison. Despite differences in cellular composition of the stem cell grafts, immune reconstitution in both groups was similar. Significantly higher levels of type 1- and 2-associated cytokine messenger ribonucleic acid (mRNA) were observed both prior to and following transplant in the peripheral blood (PB) of both cohorts as compared to normal individuals. Similar levels of interleukin (IL)-4, IL-10, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha) messenger ribonucleic acid (mRNA) were seen in PB mononuclear cells following transplant with either product. In contrast, patients receiving isolated CD34(+)Lin(-)Thy-1(lo) cells expressed significantly higher IL-2 levels at all times examined post-transplant. Despite the high levels of cytokine gene expression and rapid restoration to pretransplant levels of CD3 cell number by day 30, T cell function and CD4:CD8 and CD4(+)CD45RA:CD4(+)CD45RO(+) ratios were significantly depressed in both cohorts compared to normal donors, and significantly lower in patients transplanted with CD34(+)Lin(-)Thy-1(lo) compared to patients receiving an intact PSC product. These data suggest that the peripheral tolerance in patients receiving HDT and an autologous SCT occurs independent of graft composition, although immune function and CD4 recovery are better facilitated by transplantation of an intact product.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570320      PMCID: PMC2034447          DOI: 10.1016/j.intimp.2007.03.006

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  69 in total

1.  Long-term immune recovery after CD34+ immunoselected and unselected peripheral blood progenitor cell transplantation: a case-control study.

Authors:  L Laurenti; S Sica; F Sorà; N Piccirillo; E Ortu La Barbera; P Chiusolo; P Salutari; C Rumi; S Rutella; G Leone
Journal:  Haematologica       Date:  1999-12       Impact factor: 9.941

2.  Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests.

Authors:  F E Davies; A C Rawstron; G Pratt; R Coupe; D Clarke; A Lubenko; K Short; T J Perren; P J Selby; S Maclennan; K Major; V Woodhead; F Robinson; J A Child; G M Smith; P W Johnson; G J Morgan
Journal:  Hematol Oncol       Date:  2000-09       Impact factor: 5.271

Review 3.  The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma.

Authors:  Mary Lee H Villanueva; Julie M Vose
Journal:  Clin Adv Hematol Oncol       Date:  2006-07

Review 4.  Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.

Authors:  Auayporn Nademanee; Stephen J Forman
Journal:  Semin Hematol       Date:  2006-10       Impact factor: 3.851

Review 5.  Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.

Authors:  Gregory Lizée; Laszlo G Radvanyi; Willem W Overwijk; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

6.  Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.

Authors:  P Colombat; P Cornillet; E Deconinck; J M Tourani; M Gardembas; M Delain; J F Abgrall; C Kootz; N Milpied
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

7.  Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.

Authors:  M Michallet; T Philip; I Philip; H Godinot; C Sebban; G Salles; A Thiebaut; P Biron; F Lopez; P Mazars; N Roubi; T Leemhuis; E Hanania; C Reading; G Fine; K Atkinson; C Juttner; B Coiffier; D Fière; E Archimbaud
Journal:  Exp Hematol       Date:  2000-07       Impact factor: 3.084

8.  Telomerase activity and lymphovascular invasion in breast cancer.

Authors:  K M Mokbel; C N Parris; M Ghilchik; C N Amerasinghe; R F Newbold
Journal:  Eur J Surg Oncol       Date:  2000-02       Impact factor: 4.424

Review 9.  Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.

Authors:  Paolo Serafini; Ivan Borrello; Vincenzo Bronte
Journal:  Semin Cancer Biol       Date:  2005-09-15       Impact factor: 15.707

10.  Immune reconstitution after purified autologous and allogeneic blood stem cell transplantation compared with unmanipulated bone marrow transplantation in children.

Authors:  Wolfgang Schwinger; Daniela Weber-Mzell; Birgit Zois; Tanja Rojacher; Martin Benesch; Herwig Lackner; Hans Juergen Dornbusch; Petra Sovinz; Andrea Moser; Gerhard Lanzer; Konrad Schauenstein; Petra Ofner; Rupert Handgretinger; Christian Urban
Journal:  Br J Haematol       Date:  2006-08-22       Impact factor: 6.998

View more
  2 in total

1.  Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.

Authors:  J Wang; T R McGuire; H C Britton; J K Schwarz; F R Loberiza; J L Meza; J E Talmadge
Journal:  Clin Exp Metastasis       Date:  2015-01-25       Impact factor: 5.150

2.  The Combination of Jiedu Xiaoluo Decoction with Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Accelerates Disease Remission of Non-Hodgkin Lymphoma.

Authors:  Yu Zhang; Jingjing Xiang; Ni Zhu; Hangping Ge; Xianfu Sheng; Shu Deng; Junfa Chen; Lihong Yu; Yan Zhou; Jianping Shen
Journal:  Evid Based Complement Alternat Med       Date:  2021-01-08       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.